Exscientia

Oxford, United Kingdom All United Kingdom companies → — Founded 2012

Biotech / Drug Discovery Specialty-Focused AI

Acquired

Website Claim this company

Products

Exscientia AI-driven

Exscientia

Drug Discovery & Research

Recursion, integrating Exscientia's AI platform, pioneers AI-driven drug discovery using automated chemistry, deep learning, and robotics to accelerate the development of novel therapeutics.

Varies by collaboration and milestones

See all 1 product →

About Exscientia

Exscientia is a pharmatech company that leverages artificial intelligence (AI) and machine learning (ML) to revolutionize drug discovery and design. Their core mission is to accelerate the identification and development of novel therapeutic compounds, ultimately aiming to deliver new treatments to patients more rapidly and efficiently than traditional methods. The company’s AI-driven platform, known as Centaur Chemist™, integrates computational design with automated laboratory experimentation, allowing for the rapid generation, optimization, and testing of potential drug candidates. This approach significantly reduces the number of molecules typically required for synthesis and the overall time to reach clinical development.

For physicians, Exscientia’s technology holds the promise of a more streamlined and effective drug development pipeline. By using AI to analyze vast biological and chemical datasets, the platform can identify disease targets and design molecules with improved potency, selectivity, and pharmacokinetic properties. Exscientia has also developed a precision oncology platform that has been shown to guide treatment selection and improve patient outcomes in clinical studies for aggressive blood cancers. This involves using AI to assess the effect of various drugs on patient samples at a single-cell level, providing predictions of treatment response before therapy initiation. The company’s focus areas include oncology and rare diseases, with several AI-designed drug candidates having already entered clinical trials.

Focus Areas

Drug Discovery Oncology Rare Diseases Precision Medicine Immuno-oncology Innate Immunity

Business Intelligence

Technology

Exscientia's Centaur AI platform (also referred to as Centaur Chemist platform) utilizes generative AI, active learning, machine learning, and physics-based systems. It supports Design-Make-Test-Learn (DMTL) loops, integrating in silico design with automated laboratory systems for synthesis and testing. The platform is built using AWS technologies and draws on large language models via Amazon Bedrock.

What Physicians Need to Know

Drug Discovery Acceleration

Exscientia leverages AI to dramatically accelerate drug discovery, reducing the typical timeline from 4.5 years to 12-15 months for delivering development candidates. They aim to bring better medicines to patients faster by automating and encoding the drug discovery process.

Oncology Focus

The company has a strong internal pipeline focused on oncology, with key programs including CDK7 inhibitor GTAEXS617 for advanced solid tumors (head and neck, breast, non-small cell lung, ovarian, colorectal, pancreatic cancers) and LSD1 inhibitor EXS74539 for small cell lung cancer and acute myeloid leukemia. They utilize a functional precision oncology platform to guide treatment selection and improve patient outcomes.

Rare Diseases

Exscientia applies its AI drug discovery platform to accelerate the discovery of small molecule therapeutics for rare disease indications, aiming to address the need for precision-engineered drugs at scale.

Precision Medicine Platform

Exscientia has developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in prospective interventional clinical studies. This platform uses AI and deep learning to analyze drug action in primary human cancer tissues, enabling personalized treatment recommendations.

Immuno-oncology

Exscientia has developed AI-designed immuno-oncology drug candidates, such as the A2A receptor antagonist EXS-21546, which aims to empower the immune system by reversing the effects of high adenosine concentrations in the tumor microenvironment. They have also identified a novel multi-gene transcript signature, the adenosine burden score (ABS), for patient selection in immuno-oncology.

Innate Immunity

While specific details on innate immunity are less prominent, Exscientia's broader focus on immunology within its partnered pipeline and its work on immune-modulating drug candidates suggest an involvement in this area.

Physician Tip

For physicians, Exscientia stands out by offering the potential for **faster access to novel, precisely designed drug candidates** due to their AI-driven discovery platform. Their **functional precision oncology platform** can help guide treatment selection and potentially improve patient outcomes by testing drug responses ex vivo in patient tissue samples, moving beyond traditional genetic biomarkers to visually confirm treatment options based on cancer cell sensitivity. This approach aims to provide **personalized treatment recommendations** and identify patients most likely to benefit from specific therapies, particularly in challenging areas like advanced solid tumors and hematological cancers. The company's focus on **encoding and automating drug discovery** also suggests a commitment to developing high-quality drug candidates with optimized properties, potentially leading to safer and more effective medicines.

Exscientia's technology stack is built on an **AI-driven computational design platform** integrated with **automated physical laboratories** for synthesis and screening. They utilize **generative AI algorithms** for in silico drug design and **automated robotics** to synthesize drug candidates, enabling 24/7 lab operation with minimal human supervision. Their algorithms are trained on extensive pharmacology data, proprietary in-house data from patient tissue samples, genomics, single-cell transcriptomics, and medical literature. The company also emphasizes **model-driven adaptive design** with continuous feedback loops to refine their AI models. Collaborations with major pharmaceutical companies like Sanofi, Bristol Myers Squibb, Merck KGaA, and Sumitomo Pharma, as well as academic institutions, are crucial to their strategy, providing access to diverse datasets and expertise.

At a glance

Founded 2012

HQ Oxford, United Kingdom · United Kingdom

CEO Dave Hallett (interim CEO)

Funding Acquired

Products 1

Visit site

Products by Exscientia

1 product in the directory

Exscientia AI-driven

Exscientia

Drug Discovery & Research

Recursion, integrating Exscientia's AI platform, pioneers AI-driven drug discovery using automated chemistry, deep learning, and robotics to accelerate the development of novel therapeutics.

Varies by collaboration and milestones

What the Web Says

Exscientia is a technology-driven drug design and development company that applies AI and machine learning to discover and design novel therapeutic compounds. The company aims to create more effective medicines faster by combining precision design with integrated experimentation. In November 2024, Exscientia merged with Recursion Pharmaceuticals, combining their AI-driven drug discovery platforms. While the company has shown promise in accelerating drug design and has several molecules in clinical trials, some early clinical readouts have been mixed, and there are ongoing discussions about the overall impact of AI on R&D efficiency and the sustainability of this approach.

Overall: Mixed

Strengths

AI-driven platform accelerates drug discovery and design.
Potential to reduce time and costs associated with traditional drug development.
Focus on precision medicine and biomarker discovery.
Strategic collaborations with industry giants.
Six AI-designed molecules have entered clinical trials.
Strong scientific and technological expertise.

Limitations

Early clinical trial data has been mixed, with some programs discontinued.
Concerns about the overall impact of AI on R&D efficiency and the ability to develop truly novel therapies.
Questions regarding the sustainability of the AI-driven advantage.
Former CEO was accused and fired for sexual misconduct.
Post-merger with Recursion, there have been job cuts.
AI models can depend on incomplete or biased datasets, limiting reliability.

Based on reviews from: RateMyEmployer, Indeed.com, Axial, TopReviewed.ai, Seeking Alpha, Reddit, AWS, Endpoints News, PitchBook, Darden Report, MarketsandMarketsu2122

Last updated: 2026-10-07

Videos

News, demos, and interviews about Exscientia.

Loading videos...

Videos load interactively. If none appear, search YouTube for Exscientia →

View all on YouTube

Press & Coverage

BioPharma Dive

Recursion to absorb Exscientia in 'techbio' deal

Recursion Pharmaceuticals and Exscientia, two prominent AI-driven drug discovery companies, are merging in a deal expected to finalize in early 2025. The combined entity will retain the Recursion name and aims to create a leading end-to-end drug discovery platform.

2024-08

Exscientia

Exscientia Q2 and H1 2024 Business Update

Exscientia announced significant advancements in its pipeline, collaborations, and financial performance for Q2 and H1 2024, including the acquisition of full rights to its CDK7 inhibitor, GTAEXS617, currently in Phase 1/2 trials.

2024-08

Amazon Web Services (AWS) Press Center

Exscientia Launches AWS AI-powered Platform to Advance Drug Discovery

Exscientia is expanding its collaboration with Amazon Web Services (AWS) to leverage AWS's AI and machine learning services for its end-to-end drug discovery and automation platform. This aims to accelerate early drug development at a lower cost by integrating generative AI drug design and robotic lab automation.

2024-07

Exscientia

Exscientia Achieves Milestones for Two Programmes in Sanofi Collaboration

Exscientia announced the advancement of two discovery programs within its collaboration with Sanofi, receiving $15 million in milestone payments. Both programs have met product profile requirements for lead optimization and show high differentiation.

2024-10

Clinical Trials Arena

Exscientia outline robot and AI use in drug discovery workflow

Exscientia showcased its robotics lab in Oxfordshire, UK, at ELRIG 2024, detailing how robotics and AI automate its end-to-end drug discovery workflow, leading to increased productivity and efficiency in developing new molecules.

2024-10

NTB Kommunikasjon (via Business Wire)

Exscientia Announces Expansion of its Current Collaboration with Sanofi to Include Existing Exscientia Programme

Sanofi is adding a new discovery stage program, initially advanced by Exscientia, into their existing collaboration. Exscientia is eligible for up to $45 million in upfront and preclinical milestone payments, plus additional development, regulatory, and sales-based milestones.

2023-12

BioSpace

Exscientia Announces Sixth Molecule Created Through Generative AI Platform to Enter Clinical Stage

Exscientia announced that Sumitomo Pharma plans to initiate a Phase 1 clinical study of DSP-2342, a dual 5-HT2A/5-HT7 antagonist for psychiatric disease, marking the sixth molecule created using Exscientia's AI platform to enter clinical trials.

2023-05

Nasdaq

Blood Cancer Discovery Publication Further Validates Exscientia's AI Precision Medicine Platform for Improving Patient Outcomes

Exscientia, ETH Zurich, the Medical University of Vienna, and the Center for Molecular Medicine published research in Blood Cancer Discovery, demonstrating how deep morphology learning enhances precision medicine through image-based ex vivo drug testing.

2022-09

Frequently Asked Questions

How does Exscientia's AI-driven drug discovery platform differentiate itself in identifying novel drug candidates, particularly in oncology and rare diseases?

Exscientia's AI platform integrates vast datasets and advanced algorithms to rapidly identify and optimize novel drug candidates, predicting their properties and potential efficacy earlier in the discovery process. This approach aims to accelerate the identification of high-quality molecules with improved chances of success, especially in complex areas like oncology and rare diseases where traditional methods face significant challenges.

What specific products or drug candidates, either in development or approved, has Exscientia's platform yielded that are relevant to precision medicine or immuno-oncology?

Exscientia has several drug candidates in various stages of development, including those targeting specific pathways in oncology and immuno-oncology. While specific product names and their current trial phases would require up-to-date information, their platform is designed to generate precisely targeted therapies, often in partnership with larger pharmaceutical companies.

How does Exscientia ensure the clinical relevance and translational success of its AI-discovered drug candidates, particularly concerning patient stratification and precision medicine applications?

Exscientia's approach emphasizes the integration of patient-centric data and predictive analytics to inform drug design and development. This includes leveraging biomarkers and genetic information to identify patient populations most likely to respond to a given therapy, thereby enhancing the potential for precision medicine applications and improving translational success.

What is Exscientia's strategy for addressing unmet needs in rare diseases, and how does their AI platform contribute to overcoming the unique challenges in this therapeutic area?

Exscientia utilizes its AI platform to efficiently explore novel targets and design compounds for rare diseases, where patient populations are small and research can be challenging. Their technology aims to accelerate the identification of viable drug candidates and optimize their properties, potentially reducing the time and cost associated with developing treatments for these often-neglected conditions.

Can you elaborate on Exscientia's partnerships with pharmaceutical companies and academic institutions, and how these collaborations impact the development and commercialization of their AI-discovered drugs?

Exscientia frequently collaborates with leading pharmaceutical companies and academic institutions to leverage their respective strengths. These partnerships often involve co-development agreements, where Exscientia's AI platform identifies and optimizes drug candidates, and the partners contribute their expertise in clinical development, manufacturing, and commercialization, accelerating the path to market.

What is Exscientia's long-term vision for integrating AI into the entire drug development lifecycle, beyond initial discovery, and how might this impact future treatment paradigms in areas like innate immunity?

Exscientia aims to integrate AI across the entire drug development lifecycle, from target identification and molecule design to clinical trial optimization and patient selection. This holistic approach seeks to create a more efficient and effective drug development paradigm, potentially leading to novel therapies for complex areas like innate immunity by uncovering new biological insights and accelerating the development of targeted interventions.